MAIA Biotechnology, Inc.: directors' dealings · United States · SEC (Form 4)

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a U.S.-based clinical-stage biopharmaceutical company listed on NYSE American (NYSE) in the United States. Founded in 2018 and incorporated in Delaware in August 2018, the company is headquartered in Chicago, Illinois, with a distributed team that also operates remotely from other U.S. locations and selected international sites. MAIA is not yet a commercial-stage business; it remains a research-driven oncology developer, which means its investment profile is that of a capital-intensive small-cap biotech with binary clinical and financing milestones. The company’s core activity is the development of targeted cancer therapies, led by its flagship investigational asset ateganosine, also referred to as THIO or 6-thio-dG. Ateganosine is a first-in-class telomere-targeting agent designed to attack telomerase-active cancer cells and to be used in sequence with immune checkpoint inhibitors. MAIA is primarily focused on non-small cell lung cancer (NSCLC), especially late-line settings where patients have failed prior standard therapies. This positions the company in a highly competitive but scientifically differentiated segment of immuno-oncology. Its value proposition is based on a niche mechanism of action rather than broad platform diversification. From a clinical development perspective, MAIA has advanced its lead program through multiple key stages. The company obtained U.S. IND clearance for THIO-101, selected a development dose in Phase 2, and initiated the pivotal Phase 3 program THIO-104 in 2025. In 2026, management stated that recent financing proceeds are expected to fully fund the ongoing pivotal trial. MAIA also activated its first U.S. site for the expansion of THIO-101, adding to an already international clinical footprint that has included Europe and Australia. Additional corporate developments have included a clinical supply agreement with Roche and repeated equity financings, underscoring the company’s reliance on external capital to execute its pipeline. Recent news flow has been dominated by clinical progress and financing rather than commercial execution. MAIA announced a March 2026 underwritten public offering and later indicated that the proceeds, combined with prior capital raising, should support the Phase 3 program. The company has also continued to highlight its telomere-targeting differentiation and early efficacy signals in NSCLC. For investors, the main opportunity lies in the potential clinical validation of a novel oncology mechanism; the main risks remain execution, dilution, regulatory uncertainty, and the lack of revenue. In short, MAIA is a high-risk, high-upside U.S. listed biotech story on NYSE American, with valuation driven almost entirely by clinical data readouts and funding visibility.